Danielle Te Vruchte

Danielle Te Vruchte

Auto-generated profile, based on publicly available information

Danielle Te Vruchte

Department of Pharmacology, University of Oxford, Oxford, OX1 3QT, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Glycoconjugate Journal
Verified
Journal Article
Open access
PDF file
KWKerri-Lee Wallom
Kerri-Lee Wallom
MFMaría E. Fernández-Suárez
María E. Fernández-Suárez
DPDavid Priestman
David Priestman
DVDanielle Te Vruchte
Danielle Te Vruchte
MHMylene Huebecker
Mylene Huebecker
FPFrances M. Platt
Frances M. Platt
It is well established that lysosomal glucocerebrosidase gene (GBA) variants are a risk factor for Parkinson’s disease (PD), with increasing evidence suggesting a loss of function mechanism. One question raised by this genetic association is whether variants of genes involved in other aspects of sphingolipid metabolism are also associated with PD. Recent studies in sporadic PD have identified variants in multiple genes linked to diseases of glycosphingolipid (GSL) metabolism to be associated with PD. GSL biosynthesis is a complex pathway involving the coordinated action of multiple enzymes in the Golgi apparatus. GSL catabolism takes place in the lysosome and is dependent on the action of multiple acid hydrolases specific for certain substrates and glycan linkages. The finding that variants in multiple GSL catabolic genes are over-represented in PD in a heterozygous state highlights the importance of GSLs in the healthy brain and how lipid imbalances and lysosomal dysfunction are associated with normal ageing and neurodegenerative diseases. In this article we will explore the link between lysosomal storage disorders and PD, the GSL changes seen in both normal ageing, lysosomal storage disorders (LSDs) and PD and the mechanisms by which these changes can affect neurodegeneration.

25 July 2022 in Movement Disorders
Verified
Journal Article
Open access
DVDanielle Te Vruchte
Danielle Te Vruchte
ASAndrea Sturchio
Andrea Sturchio
DPDavid Priestman
David Priestman
PTPanagiota Tsitsi
Panagiota Tsitsi
EHEllen Hertz
Ellen Hertz
Per SvenningssonPer Svenningsson
Per Svenningsson
Background: Alteration in glycosphingolipids (GSLs) in Parkinson's disease (PD) still needs to be determined.Objectives: We evaluated if PD subjects show abnormal GSLs levels compared to healthy controls (HC) and if GSLs correlate with clinical features.Methods: We analyzed GSLs and glucosylceramide (GlcCer) in plasma using two normal‐phase high‐performance liquid chromatography assays; clinico‐demographic data were extracted.Results: Eighty PD subjects and 25 HCs were analyzed. Levels of GlcCer, GD1b, Gb4, GalNAcGA1, and b‐series were higher in PD patients than in HCs; total GSLs, GT1b, GM1a, GM3, GM2, and a‐series levels were lower in PD patients than in HCs. Changes in GSLs were present in PD subjects, with GlcCer levels similar to those in HCs. The results were similar after excluding certain GBA1 mutation carriers. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III, correlated with Gb4 and Montreal Cognitive Assessment with GD1b levels.Conclusions: Multiple GSL abnormalities in plasma were detected in patients with and without GlcCer changes, indicating a broader shift in lipid homeostasis. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

14 May 2012 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
ASAnneliese O. Speak
Anneliese O. Speak
NPNicholas Platt
Nicholas Platt
MSMariolina Salio
Mariolina Salio
DVDanielle Te Vruchte
Danielle Te Vruchte
DSDavid A. Smith
David A. Smith
FPFrances M. Platt
Frances M. Platt
Invariant natural killer T (iNKT) cells are a specialised subset of T cells that are restricted to the MHC class I like molecule, CD1d. The ligands for iNKT cells are lipids, with the canonical superagonist being α‐galactosylceramide, a non‐mammalian glycosphingolipid. Trafficking of CD1d through the lysosome is required for the development of murine iNKT cells. Niemann‐Pick type C (NPC) disease is a lysosomal storage disorder caused by dysfunction in either of two lysosomal proteins, NPC1 or NPC2, resulting in the storage of multiple lipids, including glycosphingolipids. In the NPC1 mouse model, iNKT cells are virtually undetectable, which is likely due to the inability of CD1d to be loaded with the selecting ligand due to defective lysosomal function and/or CD1d trafficking. However, in this study we have found that in NPC1 patients iNKT cells are present at normal frequencies, with no phenotypic or functional differences. In addi‐tion, antigen‐presenting cells derived from NPC1 patients are functionally competent to present several different CD1d/iNKT‐cell ligands. This further supports the hypothesis that there are different trafficking requirements for the development of murine and human iNKT cells, and a functional lysosomal/late‐endosomal compartment is not required for human iNKT‐cell development.

25 January 2024
Verified
Preprint
Open access
PDF file
DPDavid A Priestman
David A Priestman
YWYuzhe Weng
Yuzhe Weng
MSMarya Sabir
Marya Sabir
RBReuben Bush
Reuben Bush
KWKerri-Lee Wallom
Kerri-Lee Wallom
DVDanielle Te Vruchte
Danielle Te Vruchte
Interest in the role of cellular glycosphingolipids (GSLs) in health and disease led to us developing a sensitive method to analyse the full complement of GSL structures present in mammalian cells, fluids and tissues. The original qualitative method we developed was published in 2004 and measured the oligosaccharides selectively released from glycosphingolipids using a ceramide glycanase enzyme derived from the medicinal leech. We have now updated and refined this protocol with the focus on achieving sensitive and reproducible quantitation of GSLs in cell line samples. The method uses the fluorescent compound anthranilic acid (2-AA) to label oligosaccharides prior to analysis using normal-phase high-performance liquid chromatography. The labelling procedure is rapid, selective, and easy to perform. With the inclusion of a 2AA-labelled chitotriose calibration standard, it is possible to obtain accurate and reproducible molar quantities of individual GSL species.

20 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HBHenry G. Barrow
Henry G. Barrow
ZHZhuang Z. Han
Zhuang Z. Han
ANAlex S. Nicholson
Alex S. Nicholson
SSSinéad Strasser
Sinéad Strasser
DNDaniel A. Nash
Daniel A. Nash
JDJanet E. Deane
Janet E. Deane
Gangliosides are abundant neuronal glycosphingolipids, yet their roles in organizing the plasma membrane and supporting neuronal function remain poorly defined. Mutations in the biosynthetic enzymes ST3GAL5 or B4GALNT1 cause severe neurodevelopmental disorders, yet their cellular consequences are unclear. Using isogenic human iPSC-derived cortical neurons, we show that loss of these enzymes eliminates major neuronal gangliosides but produces strikingly divergent outcomes. ST3GAL5 deficiency reprograms the glycosphingolipid repertoire toward non-neuronal species and abolishes network-level electrical activity. In contrast, B4GALNT1-deficient neurons retain near-normal excitability, supported by accumulation of simple sialylated precursors (GM3/GD3). Quantitative proteomics reveals a profound loss of plasma membrane proteins, including ion channels and synaptic organizers, only in ST3GAL5-deficient neurons. These findings identify sialylated glycosphingolipids as essential scaffolds for plasma membrane organization and neuronal excitability, providing a mechanistic basis for the severe phenotype caused by loss of GM3 synthase in humans. TEASER: Human neuronal models reveal why loss of GM3 synthase causes severe neurodevelopmental disease

21 August 2025 in bioRxiv
Verified
Preprint
Open access
ASAfitz Da Silva
Afitz Da Silva
STSamuel Boris Tene Tadoum
Samuel Boris Tene Tadoum
IMIrena J.J. Muffels
Irena J.J. Muffels
RBRohit Budhraja
Rohit Budhraja
Luisa SturialeLuisa Sturiale
Luisa Sturiale
APAlexey Pshezhetsky
Alexey Pshezhetsky
Developmental delay and seizures with or without movement abnormalities (OMIM 617836) caused by heterozygous pathogenic variants in the DHDDS gene (DHDDS-CDG) is a rare genetic disease that belongs to the progressive encephalopathy spectrum. It results in developmental delay in affected children, accompanied by myoclonus, seizures, ataxia and tremor, which worsens over time. DHDDS encodes a subunit of a DHDDS/NUS1 cis-prenyltransferase ( cis- PTase), a branch point enzyme of the mevalonate pathway essential for N-linked glycosylation. We describe the first mouse model of this disease, Dhdds R37H+/- strain, heterozygous for the human recurrent de novo c.110G>A:p.R37H pathogenic variant. Dhdds R37H+/- mice present with seizures, myoclonus and memory deficits associated with reduced density or/and maturity of inhibitory interneurons in the cortex. Multiomics analyses of mouse CNS tissues, together with the enzymatic/structural characterization of the R37H DHDDS mutant protein, reveal that the variant produces a catalytically inactive enzyme and results in a brain dolichol deficit, aberrant glycosylation of brain glycoproteins, including those involved in synaptic transmission, and major perturbations in the CNS proteome and lipidome. Acetazolamide, a carbonic anhydrase inhibitor clinically approved for treatment of glaucoma, epilepsy, and intracranial hypertension, and successfully used “off-label” to treat genetic movement disorders, drastically reduces seizure susceptibility to pentylenetetrazol in Dhdds R37H+/- mice, suggesting potential therapeutic value of using this drug in human DHDDS-CDG patients. Together, our results define cis- PTase as a master regulator of CNS development and function and establish that its monoallelic debilitating variants cause a novel Congenital Disorder of Glycosylation, associated with aberrant levels of neuronal proteins and lipids. Graphical